{"id":12428,"date":"2021-06-15T16:45:01","date_gmt":"2021-06-15T11:15:01","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12428"},"modified":"2021-07-24T12:58:26","modified_gmt":"2021-07-24T07:28:26","slug":"medtech-wrap-up","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up","title":{"rendered":"Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0048aeef9ab\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0048aeef9ab\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Eclipse_Launches_MicroPen_EVO%E2%84%A2_Advanced_Micro-needling_Device\" >Eclipse Launches MicroPen EVO&#x2122; Advanced Micro-needling Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Aethlon_Medical_Publishes_Case_Studies_of_Two_Critically_Ill_COVID-19_Patients_Treated_with_the_Hemopurifier%C2%AE\" >Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier\u00ae<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Medtronic_to_Stop_Distribution_and_Sale_of_HVAD%E2%84%A2_System\" >Medtronic to Stop Distribution and Sale of HVAD&#x2122; System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Cognoa_Receives_FDA_Marketing_Authorization_for_First-of-its-kind_Autism_Diagnosis_Aid\" >Cognoa Receives FDA Marketing Authorization for First-of-its-kind Autism Diagnosis Aid&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#ObvioHealth_announces_a_ground-breaking_partnership_with_Dedalus_Group_to_unite_real-world_clinical_trial_data\" >ObvioHealth announces a ground-breaking partnership with Dedalus Group to unite real-world &amp; clinical trial data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#HistoSonics_Announces_First_Patient_Treated_in_European_Clinical_Trial\" >HistoSonics Announces First Patient Treated in European Clinical Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#FDA_Approves_First-of-its-Kind_SenSight%E2%84%A2_Directional_Lead_System_for_DBS_Therapy\" >FDA Approves First-of-its-Kind SenSight&#x2122; Directional Lead System for DBS Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#FitTrack_Partners_with_Advanced_Human_Imaging_AHI_to_Integrate_New_State-of-the-Art_Body_Scanning\" >FitTrack Partners with Advanced Human Imaging (AHI) to Integrate New State-of-the-Art Body Scanning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Ibex_Granted_FDA_Breakthrough_Device_Designation\" >Ibex Granted FDA Breakthrough Device Designation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\/#Medtronic_Received_FDA_Approval_of_its_Next_Generation_Recharge-Free_Spinal_Cord_Stimulation_Platform\" >Medtronic Received FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-eclipse-launches-micropen-evo-advanced-micro-needling-device\"><span class=\"ez-toc-section\" id=\"Eclipse_Launches_MicroPen_EVO%E2%84%A2_Advanced_Micro-needling_Device\"><\/span><strong>Eclipse Launches MicroPen EVO&#x2122; Advanced Micro-needling Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 01, 2021, Eclipse<\/strong>, a leading aesthetic and medical manufacturer, received FDA clearance of their latest medical-grade micro-needling device, the <strong>MicroPen EVO<\/strong>. It had launched MicroPen EVO in Canada last year and now will make it available to dermatology and aesthetic practices in the United States.<\/p>\n\n\n\n<p>Tom O&#8217;Brien, CEO, and Founder of Eclipse said, \u201cWe are very excited to announce the FDA clearance of the MicroPen EVO. This represents the start of multigenerational product offerings that will propel Eclipse for many years to come.&#8221;<\/p>\n\n\n\n<p>Eclipse first entered the micro-needling device industry with the MicroPen, widely regarded as the premier pen at its launch. In 2015, the MicroPen Elite was launched, introducing both form factor and technological improvements. Together, the two MicroPen products made Eclipse the industry leader in micro-needling devices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aethlon-medical-publishes-case-studies-of-two-critically-ill-covid-19-patients-treated-with-the-hemopurifier\"><span class=\"ez-toc-section\" id=\"Aethlon_Medical_Publishes_Case_Studies_of_Two_Critically_Ill_COVID-19_Patients_Treated_with_the_Hemopurifier%C2%AE\"><\/span><strong>Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier\u00ae<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 03, 2021, Aethlon Medical, Inc.<\/strong> announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier\u00ae, titled &#8220;<strong>Removal of COVID-19 Spike Protein, Whole Virus, Exosomes and Exosomal microRNAs by the Hemopurifier\u00ae Lectin-Affinity Cartridge in Critically Ill Patients with COVID-19 Infection<\/strong>&#8221; and was published in Research Square. The patients were given access to Hemopurifier\u00ae treatment through Emergency Use.&nbsp;<\/p>\n\n\n\n<p>The cartridge is made to filter viruses and exosomes from the blood and was used for nine sessions in two critically ill <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 <\/a>patients. The first patient showed improvement in COVID-19 associated coagulopathy (CAC), lung injury, inflammation, and tissue injury despite the absence of demonstrable COVID-19 viremia. This patient received eight Hemopurifier treatments without complications and eventually was weaned from a ventilator and was discharged from the hospital.<\/p>\n\n\n\n<p>The second patient was notable for the first-ever demonstration of in vivo removal of the SARS-CoV-2 virus from the bloodstream of an infected patient. The patient completed a six-hour Hemopurifier\u00ae treatment without complications and subsequently was placed on Continuous Renal Replacement Therapy (CRRT). The patient ultimately expired three hours after being placed on CRRT because of the advanced stage of the disease.<\/p>\n\n\n\n<p>In addition to the two case studies, the safety and feasibility of the Aethlon Hemopurifier\u00ae is being evaluated in an active Early Feasibility Study, analogous to a Phase 1 clinical trial for a drug or biologic, that will enroll up to 40 COVID-19 ICU patients [NCT04595903]. The pre-print manuscript is being submitted to peer-reviewed journals, and Aethlon expects it to be published in the near future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-to-stop-distribution-and-sale-of-hvad-system\"><span class=\"ez-toc-section\" id=\"Medtronic_to_Stop_Distribution_and_Sale_of_HVAD%E2%84%A2_System\"><\/span><strong>Medtronic to Stop Distribution and Sale of HVAD&#x2122; System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 03, 2021, Medtronic plc<\/strong> announced that it is <strong>stopping<\/strong> the distribution and sale of the <strong>Medtronic HVAD&#x2122; System<\/strong>. The physicians were notified by the company to cease new implants of the HVAD System and transition to an alternative means of durable mechanical circulatory support.<\/p>\n\n\n\n<p>This action was initiated in light of a growing body of observational clinical comparisons indicating a higher frequency of neurological adverse events, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/ischemic-stroke-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">stroke<\/a> and mortality, with the HVAD System as compared to other circulatory support devices available to patients.<\/p>\n\n\n\n<p>Nnamdi Njoku, president of the Mechanical Circulatory Support business, which is part of the Cardiovascular Portfolio at Medtronic, said, \u201cThe Medtronic Mission guides us to always do what is in the best interests of patients and that is exactly what we are doing and will do for those impacted by this decision. There is nothing more important than the safety and well-being of patients. We recognize this information may be concerning for patients and their caregivers, and Medtronic is committed to supporting them in coordination with their physicians.&#8221;<\/p>\n\n\n\n<p>&nbsp;Medtronic is committed to patient safety and serves the needs of the approximately 4,000 HVAD patients currently implanted with the device.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cognoa-receives-fda-marketing-authorization-for-first-of-its-kind-autism-diagnosis-aid\"><span class=\"ez-toc-section\" id=\"Cognoa_Receives_FDA_Marketing_Authorization_for_First-of-its-kind_Autism_Diagnosis_Aid\"><\/span><strong>Cognoa Receives FDA Marketing Authorization for First-of-its-kind Autism Diagnosis Aid&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 02, 2021, Cognoa<\/strong>, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, received approval for a <strong>De Novo classification<\/strong> request from the<strong> <\/strong>U.S. Food and Drug Administration (FDA) for its <strong>autism diagnosis aid<\/strong>. The AI-based device is intended for use by healthcare providers as an aid in the diagnosis of <a href=\"https:\/\/www.delveinsight.com\/report-store\/autism-spectrum-disorder-asd-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">autism spectrum disorder (ASD<\/a>) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider.<\/p>\n\n\n\n<p>Dave Happel, CEO of Cognoa, said, &#8220;The current system is already at a breaking point as it is unable to provide early diagnoses and intervention opportunities to many children and families. With rapidly-rising autism rates, this crisis will only worsen without new approaches and innovations. The FDA authorization of our diagnosis aid, Canvas Dx&#x2122;, is a significant milestone in Cognoa&#8217;s development and a crucial step towards making early diagnoses more accessible to children and families &#8211; regardless of gender, ethnicity, race, zip code, or socio-economic background. We look forward to partnering with the healthcare community as we introduce Canvas Dx in the coming months.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-obviohealth-announces-a-ground-breaking-partnership-with-dedalus-group-to-unite-real-world-clinical-trial-data\"><span class=\"ez-toc-section\" id=\"ObvioHealth_announces_a_ground-breaking_partnership_with_Dedalus_Group_to_unite_real-world_clinical_trial_data\"><\/span><strong>ObvioHealth announces a ground-breaking partnership with Dedalus Group to unite real-world &amp; clinical trial data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 07, 2021, <\/strong>ObvioHealth, a global virtual research organization (VRO), entered into a new strategic partnership with Dedalus Group, the leading healthcare and diagnostic software solutions provider in Europe. The partnership will be supporting healthcare providers from 6000+ hospitals and clinics across the world to deliver care to more than 330 million patients by uniting ObvioHealth&#8217;s proprietary decentralized clinical trial tools with Dedalus&#8217;s software solutions and connecting the dots between clinical research and EHR (Electronic Health Record) data.<\/p>\n\n\n\n<p>Ivan Jarry, CEO of ObvioHealth, said, \u201cAt a time when personalized medicine is on the rise and the ROI on drug development is declining, we must make research dollars work harder. There is tremendous and rich data available on any number of disease states, comorbidities and biomarkers that can inform clinical trials. The integration of clinical research with the data that sits within EHRs has the potential to be a game changer. Dedalus and ObvioHealth are enabling more precise identification of cohorts for trials while also facilitating longitudinal analyses that can identify new indications and\/or long-term impacts of certain treatments.&#8221;<\/p>\n\n\n\n<p>Dr. Michael Dahlweid, MD, Ph.D., the Chief Product &amp; Clinical Officer at Dedalus Group, said, &#8220;With this partnership, we are aiming to improve translational medicine through a spectrum of options: from decentralized trials\u2026all the way to synthetic trials, leveraging the full potential of existing real-world data to allow for clinical learning and validation of all kinds of therapeutical approaches.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-histosonics-announces-first-patient-treated-in-european-clinical-trial\"><span class=\"ez-toc-section\" id=\"HistoSonics_Announces_First_Patient_Treated_in_European_Clinical_Trial\"><\/span><strong>HistoSonics Announces First Patient Treated in European Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 07, 2021, HistoSonics<\/strong>, developer of a non-invasive platform and novel sonic beam therapy, announced that the first patient has been treated as part of the company&#8217;s <strong>#HOPE4LIVER Europe Trial<\/strong>, which was approved by German authorities earlier in the year.&nbsp;<\/p>\n\n\n\n<p>This study is designed to evaluate the safety and efficacy of the HistoSonics&#8217; platform technology, which uses the novel science of histotripsy and the mechanical properties of therapeutic focused ultrasound, to destroy unwanted tissue, including targeted primary and metastatic liver tumors, without the need for incisions or invasiveness. It is a multi-center, open-label, single-arm trial planned to enroll up to 45 patients throughout Spain, Italy, UK, and Germany and is being run in parallel with a similar US trial.<\/p>\n\n\n\n<p>HistoSonics&#8217; Vice President of Medical Affairs, Joe Amaral, M.D., said, &#8220;It is extremely exciting to be working with Professor Pech and the team at Otto con Guericke University Clinic in Magdeburg to build upon the company&#8217;s initial success of the THERESA Study conducted in Spain.&nbsp; We believe our non-invasive platform and novel therapy has the potential to change the experience for patients with solid liver tumors, and our aim is to continue to build this evidence with the #HOPE4LIVER Trials.&nbsp; We are very thankful to Professor Pech and the entire team in Magdeburg for their continued commitment to clinical research and providing leadership in this important trial.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-first-of-its-kind-sensight-directional-lead-system-for-dbs-therapy\"><span class=\"ez-toc-section\" id=\"FDA_Approves_First-of-its-Kind_SenSight%E2%84%A2_Directional_Lead_System_for_DBS_Therapy\"><\/span><strong>FDA Approves First-of-its-Kind SenSight&#x2122; Directional Lead System for DBS Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 07, 2021, <\/strong>Medtronic plc received approval from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> and performed the first U.S. implants of the <strong>SenSight&#x2122; Directional Lead System<\/strong> used for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/deep-brain-stimulation-devices-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Deep Brain Stimulation (DBS) therapy<\/a><\/strong>.<\/p>\n\n\n\n<p>SenSight is the first-of-its-kind DBS directional lead that combines the benefits of directionality with the power of sensing, allowing physicians to deliver precise, patient-specific DBS therapy for the treatment of some symptoms associated with movement disorders like Parkinson&#8217;s disease, dystonia, and essential tremor, and medically refractory <a href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\/\" target=\"_blank\" rel=\"noreferrer noopener\">epilepsy<\/a>.<\/p>\n\n\n\n<p>The system was first implanted at the University of Florida by multi-disciplinary teams in early June, and a full launch in the U.S. will continue immediately. The product also recently received CE Mark and fully launched in Western Europe in March of 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fittrack-partners-with-advanced-human-imaging-ahi-to-integrate-new-state-of-the-art-body-scanning\"><span class=\"ez-toc-section\" id=\"FitTrack_Partners_with_Advanced_Human_Imaging_AHI_to_Integrate_New_State-of-the-Art_Body_Scanning\"><\/span><strong>FitTrack Partners with Advanced Human Imaging (AHI) to Integrate New State-of-the-Art Body Scanning<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 09, 2021, FitTrack<\/strong> entered into a partnership with human imaging company <strong>Advanced Human Imaging (AHI)<\/strong> to announce <strong>FitScan<\/strong>.<\/p>\n\n\n\n<p>It plans to launch the innovative software in early 2022 across iOS and Android platforms. FitScan will enable its users to check privately, track, accurately assess overall wellness, and predict potential health risks all from their smartphone. The new software will seamlessly integrate into FitTrack&#8217;s existing ecosystem, which includes an app and multiple hardware devices, to deliver a complete and holistic perspective of health, wellness, and progress.<\/p>\n\n\n\n<p>The <strong>Face Assessment<\/strong> is a non-intrusive and easy-to-use scan for measuring key health parameters, such as heart rate, blood pressure, respiratory rate, and risks associated with cardiovascular disease, heart attacks, and strokes. FitScan&#8217;s <strong>Body Assessment<\/strong> scan will associate innovative technology and state-of-the-art image processing techniques that return over ten unique insights such as body circumference, body composition, and risk indicators for obesity and type-2 diabetes.<\/p>\n\n\n\n<p>Jeffrey Lee, CEO, and Founder of FitTrack, said, &#8220;It has always been my vision to ensure better health outcomes for our customers by making health management simple and sustainable. We want to give our users the tools to take control of their personal health journeys. With AHI as our software partner, we are enabling FitTrack users to use their personal devices to perform simple but cutting-edge health assessments in the safety and comfort of their home. FitScans are self-reported with instant results, at a fraction of the cost of a doctor visit or dexa scan.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ibex-granted-fda-breakthrough-device-designation\"><span class=\"ez-toc-section\" id=\"Ibex_Granted_FDA_Breakthrough_Device_Designation\"><\/span><strong>Ibex Granted FDA Breakthrough Device Designation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 09, 2021, <\/strong>Ibex Medical Analytics, the pioneer in <strong>AI-powered cancer diagnostics<\/strong>, received the <strong>Breakthrough Device Designation<\/strong> by the U.S. Food and Drug Administration (FDA) for its Galen platform.&nbsp;<\/p>\n\n\n\n<p>Joseph Mossel, Chief Executive Officer and Co-Founder of Ibex Medical Analytics, said, &#8220;We are honored to have been granted the Breakthrough Device Designation. Ibex is committed to providing world-class tools for pathologists to ensure every patient receives a timely and correct diagnosis while supporting pathology labs and health systems to increase efficiency and accuracy. Our Strong AI technology is already in clinical use globally, making a real impact on patient care. We are proud to work closely with the FDA and look forward to continuing to collaborate with the agency as we accelerate our clinical program in the United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-received-fda-approval-of-its-next-generation-recharge-free-spinal-cord-stimulation-platform\"><span class=\"ez-toc-section\" id=\"Medtronic_Received_FDA_Approval_of_its_Next_Generation_Recharge-Free_Spinal_Cord_Stimulation_Platform\"><\/span><strong>Medtronic Received FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 10, 2021, Medtronic plc<\/strong> received <strong>U.S. Food and Drug Administration (FDA) approval<\/strong> for <strong>Vanta<\/strong>&#x2122;, a high-performance, <strong>recharge-free implantable neurostimulator (INS)<\/strong> with a device like that can be optimized for up to 11 years.&nbsp;<\/p>\n\n\n\n<p>The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced&#x2122;, Medtronic&#8217;s previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator, with a more rounded, ergonomic contouring to offer enhanced comfort. It also utilizes Medtronic&#8217;s proprietary AdaptiveStim&#x2122; technology for personalized pain relief that adapts to the patient&#8217;s movement or body position using a built-in accelerometer.<\/p>\n\n\n\n<p>Charlie Covert, vice president, and general manager, Pain Therapies within the <a href=\"https:\/\/www.delveinsight.com\/blog\/neuromodulation-devices\/?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Neuromodulation<\/a> business, which is part of the Neuroscience Portfolio at Medtronic, said, &#8220;We are committed to delivering innovative solutions that meets the needs of every patient. For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eclipse Launches MicroPen EVO&#x2122; Advanced Micro-needling Device On June 01, 2021, Eclipse, a leading aesthetic and medical manufacturer, received FDA clearance of their latest medical-grade micro-needling device, the MicroPen EVO. It had launched MicroPen EVO in Canada last year and now will make it available to dermatology and aesthetic practices in the United States. Tom [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17056,628,17059,16773,17060,16744,17020,17021,16975,16968,16775,17058],"industry":[17226,17225],"therapeutic_areas":[17242,17229,17245],"class_list":["post-12428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aethlon","tag-autism","tag-cognoa","tag-deep-brain-stimulation","tag-eclipse","tag-epilepsy-market","tag-medical-devices","tag-medical-devices-market","tag-medtech-market","tag-medtronic","tag-neuromodulation","tag-obviohealth","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech Wrap Up | Medical Devices and Companies in the News<\/title>\n<meta name=\"description\" content=\"Eclipse, Medtronic, Aethlon, HistoSonics,FitTrack, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech Wrap Up | Medical Devices and Companies in the News\" \/>\n<meta property=\"og:description\" content=\"Eclipse, Medtronic, Aethlon, HistoSonics,FitTrack, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-15T11:15:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech Wrap Up | Medical Devices and Companies in the News","description":"Eclipse, Medtronic, Aethlon, HistoSonics,FitTrack, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up","og_locale":"en_US","og_type":"article","og_title":"MedTech Wrap Up | Medical Devices and Companies in the News","og_description":"Eclipse, Medtronic, Aethlon, HistoSonics,FitTrack, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-06-15T11:15:01+00:00","article_modified_time":"2021-07-24T07:28:26+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up","url":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up","name":"MedTech Wrap Up | Medical Devices and Companies in the News","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth.jpg","datePublished":"2021-06-15T11:15:01+00:00","dateModified":"2021-07-24T07:28:26+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Eclipse, Medtronic, Aethlon, HistoSonics,FitTrack, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-wrap-up#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth.jpg","width":772,"height":482,"caption":"MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/15182920\/MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aethlon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Autism<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cognoa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Deep brain stimulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eclipse<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epilepsy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medtronic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromodulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ObvioHealth<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aethlon<\/span>","<span class=\"advgb-post-tax-term\">Autism<\/span>","<span class=\"advgb-post-tax-term\">Cognoa<\/span>","<span class=\"advgb-post-tax-term\">Deep brain stimulation<\/span>","<span class=\"advgb-post-tax-term\">Eclipse<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy market<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Medtronic<\/span>","<span class=\"advgb-post-tax-term\">Neuromodulation<\/span>","<span class=\"advgb-post-tax-term\">ObvioHealth<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 15, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 15, 2021 4:45 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"MedTech-News-updates-Eclipse-Medtronic-Aethlon-Cognoa-ObvioHealth","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12428"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12428\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12436"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12428"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12428"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}